These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30187811)

  • 21. Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia.
    Sarsotti E; Marugan I; Benet I; Terol MJ; Sanchez-Izquierdo D; Tormo M; Rubio-Moscardo F; Martinez-Climent JA; García-Conde J
    Leukemia; 2004 Apr; 18(4):743-6. PubMed ID: 14961033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.
    Mackus WJ; Kater AP; Grummels A; Evers LM; Hooijbrink B; Kramer MH; Castro JE; Kipps TJ; van Lier RA; van Oers MH; Eldering E
    Leukemia; 2005 Mar; 19(3):427-34. PubMed ID: 15674362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.
    Schwänen C; Hecker T; Hübinger G; Wölfle M; Rittgen W; Bergmann L; Karakas T
    Leukemia; 2002 Oct; 16(10):2096-105. PubMed ID: 12357363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
    Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
    Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
    Trojani A; Montillo M; Nichelatti M; Tedeschi A; Colombo C; Veronese S; Mura MA; Ricci F; Scarpati B; Colosimo A; Lodola M; Morra E
    Cancer Biomark; 2010; 6(1):1-9. PubMed ID: 20164537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
    Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
    Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.
    Seymour EK; Ruterbusch JJ; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2019 Jan; 125(1):135-143. PubMed ID: 30343488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
    Christodoulopoulos G; Fotouhi N; Krajewski S; Reed JC; Alaoui-Jamali M; Panasci L
    Cancer Lett; 1997 Dec; 121(1):59-67. PubMed ID: 9459175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High CXCR3 on Leukemic Cells Distinguishes
    Manukyan G; Papajik T; Mikulkova Z; Urbanova R; Kraiczova VS; Savara J; Kudelka M; Turcsanyi P; Kriegova E
    J Immunol Res; 2020; 2020():7084268. PubMed ID: 32802894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
    Veldurthy A; Patz M; Hagist S; Pallasch CP; Wendtner CM; Hallek M; Krause G
    Blood; 2008 Aug; 112(4):1443-52. PubMed ID: 18550857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL.
    Crowther-Swanepoel D; Wild R; Sellick G; Dyer MJ; Mauro FR; Cuthbert RJ; Jonsson V; Matutes E; Dearden C; Wiley J; Fuller S; Catovsky D; Houlston RS
    Blood; 2008 Jun; 111(12):5691-3. PubMed ID: 18424666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteins interaction network and modeling of IGVH mutational status in chronic lymphocytic leukemia.
    Álvarez-Silva MC; Yepes S; Torres MM; Barrios AF
    Theor Biol Med Model; 2015 Jun; 12():12. PubMed ID: 26088082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgVH gene mutation status and genomic imbalances in chronic lymphocytic leukaemia with increased prolymphocytes (CLL/PL).
    Balogh Z; Reiniger L; Deák L; Bödör C; Csomor J; Szepesi A; Gagyi E; Kopper L; Matolcsy A
    Hematol Oncol; 2007 Jun; 25(2):90-5. PubMed ID: 17410523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols.
    Matthews C; Catherwood M; Morris TC; Alexander HD
    Leuk Lymphoma; 2004 Sep; 45(9):1899-904. PubMed ID: 15223652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia.
    Smolej L; Andrys C; Peková S; Schwarz J; Belada D; Zák P
    Haematologica; 2006 Oct; 91(10):1432-3. PubMed ID: 17018398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.